Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors
Status:
Recruiting
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
This study is a single arm, pilot study of Sunitinib in patient with RET fusion positive,
FGFR2 fusion/FGFR mutation Refractory solid tumor and/or specific sensitivity to Sunitinib by
Avatar scan that has progressed following standard therapy or that has not responded to
standard therapy or for which there is no standard therapy.
To investigate the efficacy and safety of Sunitinib in patient with Refractory solid tumor.